Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.49 |
| ▸ | PPARA | Q07869 | 4/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | LAP3 | P28838 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5691409 | 0.86 | ALDH1A1 (0.54) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL5994737 | 0.85 | LTA4H (0.61) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL3938267 | 0.84 | PPARA (0.61) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL5689171 | 0.82 | PPARD (0.47) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL9087273 | 0.82 | LTA4H (0.64) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL6093003 | 0.79 | PPARG (0.50) | FFAR1PPARGPPARASMN1; SMN2 | |
| SCHEMBL6092980 | 0.79 | PPARA (0.55) | LTA4HFFAR1PPARGPPARA | |
| SCHEMBL5700 | 0.76 | LTA4H (0.80) | LTA4HFFAR1FFAR4EPHX2MAOB | |
| SCHEMBL21366441 | 0.76 | LTA4H (0.68) | LTA4HFFAR1FFAR4PPARGPPARA | |
| SCHEMBL2164928 | 0.76 | LTA4H (0.72) | LTA4HFFAR1FFAR4PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1835917-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-09-20 | — | — | CN | disclosed |
| US-20060199857-A1 | Therapeutic agents | ASTRAZENECA UK LIMITED (GB) | 2006-09-07 | — | — | US | disclosed |
| EP-1638927-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2006-03-29 | — | — | EP | disclosed |
| WO-2004113282-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199857-A1 | Therapeutic agents | PNLIP, LIPC, GPR119 | LTA4H 1267/4885FFAR1 60/4885FFAR4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.